# Primerica, Inc.: financial statements, quarterly

PRI · NYSE · CIK 1475922 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pri.md) · [Financials](/companies/pri/financials.md) · [Filings](/companies/pri/filings.md) · [Insiders](/companies/pri/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pri/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [697](/filings/0000950170-25-029882.md) | [706](/filings/0000950170-25-029882.md) | [736](/filings/0000950170-25-066724.md) | [791](/filings/0000950170-25-104779.md) | [774](/filings/0001193125-25-268668.md) | [788](/filings/0000950170-25-029882.md) | [805](/filings/0001193125-26-211397.md) | [793](/filings/0001193125-26-337365.md) | [840](/filings/0001193125-25-268668.md) | [854 d](/filings/0001193125-26-082233.md) | [873](/filings/0001193125-26-211397.md) | [865](/filings/0001193125-26-337365.md) |
| Cost of revenue | $m | [12.6](/filings/0000950170-23-060945.md) | [15.1 d](/filings/0000950170-24-022262.md) | [13.5](/filings/0000950170-24-054347.md) | [15.7](/filings/0000950170-24-093765.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [6.6](/filings/0000950170-24-123110.md) | [6.6 d](/filings/0000950170-24-022262.md) | [6.8](/filings/0000950170-25-066724.md) | [6.1](/filings/0000950170-25-104779.md) | [6.1](/filings/0001193125-25-268668.md) | not reported | [6.0](/filings/0000950170-25-066724.md) | [6.0](/filings/0000950170-25-104779.md) | [6.0](/filings/0001193125-25-268668.md) | not reported | not reported | not reported |
| Income tax | $m | [48.9](/filings/0000950170-25-029882.md) | [46.0](/filings/0000950170-25-029882.md) | [45.0](/filings/0000950170-25-066724.md) | [63.5](/filings/0000950170-25-104779.md) | [59.8](/filings/0001193125-25-268668.md) | [50.8](/filings/0000950170-25-029882.md) | [52.3](/filings/0001193125-26-211397.md) | [56.2](/filings/0001193125-26-337365.md) | [64.9](/filings/0001193125-25-268668.md) | [50.0 d](/filings/0001193125-26-082233.md) | [59.3](/filings/0001193125-26-211397.md) | [55.9](/filings/0001193125-26-337365.md) |
| Net income | $m | [152](/filings/0000950170-23-060945.md) | [152](/filings/0000950170-25-029882.md) | [138](/filings/0000950170-24-054347.md) | [1.2](/filings/0000950170-24-093765.md) | [164](/filings/0001193125-25-268668.md) | [167](/filings/0000950170-25-029882.md) | [169](/filings/0001193125-26-211397.md) | [178](/filings/0001193125-26-337365.md) | [207](/filings/0001193125-25-268668.md) | [197 d](/filings/0001193125-26-082233.md) | [190](/filings/0001193125-26-211397.md) | [202](/filings/0001193125-26-337365.md) |
| Diluted EPS | $ per share | [4.23](/filings/0000950170-25-029882.md) | [4.30](/filings/0000950170-25-029882.md) | [3.93](/filings/0000950170-25-066724.md) | [0.03](/filings/0000950170-25-104779.md) | [4.83](/filings/0001193125-25-268668.md) | [4.96](/filings/0000950170-25-029882.md) | [5.05](/filings/0001193125-26-211397.md) | [5.40](/filings/0001193125-26-337365.md) | [6.35](/filings/0001193125-25-268668.md) | not reported | [5.97](/filings/0001193125-26-211397.md) | [6.45](/filings/0001193125-26-337365.md) |
| Basic EPS | $ per share | [4.23](/filings/0000950170-25-029882.md) | [4.30](/filings/0000950170-25-029882.md) | [3.94](/filings/0000950170-25-066724.md) | [0.03](/filings/0000950170-25-104779.md) | [4.84](/filings/0001193125-25-268668.md) | [4.97](/filings/0000950170-25-029882.md) | [5.06](/filings/0001193125-26-211397.md) | [5.41](/filings/0001193125-26-337365.md) | [6.36](/filings/0001193125-25-268668.md) | not reported | [5.98](/filings/0001193125-26-211397.md) | [6.46](/filings/0001193125-26-337365.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.5](/filings/0000950170-23-060945.md) | [0.6](/filings/0000950170-25-029882.md) | [0.6](/filings/0000950170-24-054347.md) | [0.6](/filings/0000950170-24-093765.md) | [0.6](/filings/0000950170-24-123110.md) | [0.7](/filings/0001193125-26-082233.md) | [0.6](/filings/0000950170-25-066724.md) | [0.6](/filings/0000950170-25-104779.md) | [0.6](/filings/0001193125-25-268668.md) | [0.8](/filings/0001193125-26-337365.md) | [0.6](/filings/0001193125-26-211397.md) | [0.6](/filings/0001193125-26-337365.md) |
| Total assets | $bn | [14.4](/filings/0000950170-23-060945.md) | [15.0](/filings/0000950170-25-029882.md) | [14.9](/filings/0000950170-24-054347.md) | [14.6](/filings/0000950170-24-093765.md) | [14.8](/filings/0000950170-24-123110.md) | [14.6](/filings/0001193125-26-082233.md) | [14.6](/filings/0000950170-25-066724.md) | [14.8](/filings/0000950170-25-104779.md) | [14.8](/filings/0001193125-25-268668.md) | [15.0](/filings/0001193125-26-337365.md) | [14.7](/filings/0001193125-26-211397.md) | [14.8](/filings/0001193125-26-337365.md) |
| Total liabilities | $bn | [12.1](/filings/0000950170-23-060945.md) | [13.0](/filings/0000950170-25-029882.md) | [12.7](/filings/0000950170-24-054347.md) | [12.4](/filings/0000950170-24-093765.md) | [12.9](/filings/0000950170-24-123110.md) | [12.3](/filings/0001193125-26-082233.md) | [12.3](/filings/0000950170-25-066724.md) | [12.5](/filings/0000950170-25-104779.md) | [12.6](/filings/0001193125-25-268668.md) | [12.6](/filings/0001193125-26-337365.md) | [12.2](/filings/0001193125-26-211397.md) | [12.3](/filings/0001193125-26-337365.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [2.3](/filings/0000950170-24-123110.md) | [2.1](/filings/0001193125-26-082233.md) | [2.2](/filings/0000950170-25-066724.md) | [2.1](/filings/0000950170-25-104779.md) | [1.9](/filings/0001193125-25-268668.md) | [2.3](/filings/0001193125-26-082233.md) | [2.3](/filings/0001193125-26-211397.md) | [2.3](/filings/0001193125-26-337365.md) | [2.3](/filings/0001193125-25-268668.md) | [2.4](/filings/0001193125-26-337365.md) | [2.5](/filings/0001193125-26-211397.md) | [2.5](/filings/0001193125-26-337365.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [140 d](/filings/0000950170-24-123110.md) | [241 d](/filings/0001193125-26-082233.md) | [211](/filings/0000950170-25-066724.md) | [173 d](/filings/0000950170-25-104779.md) | [207 d](/filings/0001193125-25-268668.md) | [271 d](/filings/0001193125-26-082233.md) | [197](/filings/0001193125-26-211397.md) | [163 d](/filings/0001193125-26-337365.md) | [203 d](/filings/0001193125-25-268668.md) | [338 d](/filings/0001193125-26-082233.md) | [157](/filings/0001193125-26-211397.md) | [194 d](/filings/0001193125-26-337365.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [23.3 d](/filings/0000950170-24-123110.md) | [22.9 d](/filings/0001193125-26-082233.md) | [26.3](/filings/0000950170-25-066724.md) | [25.8 d](/filings/0000950170-25-104779.md) | [30.5 d](/filings/0001193125-25-268668.md) | [30.2 d](/filings/0001193125-26-082233.md) | [34.7](/filings/0001193125-26-211397.md) | [34.2 d](/filings/0001193125-26-337365.md) | [33.8 d](/filings/0001193125-25-268668.md) | [33.3 d](/filings/0001193125-26-082233.md) | [38.1](/filings/0001193125-26-211397.md) | [37.5 d](/filings/0001193125-26-337365.md) |
| Share repurchases | $m | [106 d](/filings/0000950170-24-123110.md) | [72.5 d](/filings/0001193125-26-082233.md) | [109](/filings/0000950170-25-066724.md) | [143 d](/filings/0000950170-25-104779.md) | [129 d](/filings/0001193125-25-268668.md) | [44.4 d](/filings/0001193125-26-082233.md) | [118](/filings/0001193125-26-211397.md) | [129 d](/filings/0001193125-26-337365.md) | [133 d](/filings/0001193125-25-268668.md) | [70.1 d](/filings/0001193125-26-082233.md) | [135](/filings/0001193125-26-211397.md) | [135 d](/filings/0001193125-26-337365.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [37.5](/filings/0000950170-23-060945.md) | [36.8](/filings/0000950170-24-054347.md) | [36.3](/filings/0000950170-24-093765.md) | [35.8](/filings/0000950170-24-123110.md) | [34.9](/filings/0000950170-25-066724.md) | [34.4](/filings/0000950170-25-104779.md) | [33.9](/filings/0001193125-25-268668.md) | [33.3](/filings/0001193125-26-211397.md) | [32.9](/filings/0001193125-26-337365.md) | [32.5](/filings/0001193125-25-268668.md) | [31.7](/filings/0001193125-26-211397.md) | [31.2](/filings/0001193125-26-337365.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,777,350 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-337365.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.